(Q51906679)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Loes Leenen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Bootsma HP

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Ricker L

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Diepman L

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Gehring J

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Hulsman J

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Lambrechts D

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Schellekens A

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

de Krom M

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Aldenkamp AP

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

20 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

296-303

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17317325%20AND%20SRC:MED&resulttype=core&format=json

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Topiramate: a new antiepileptic drug for refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

A prospective analysis of the outcome of levetiracetam in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

The long term retention of levetiracetam in a large cohort of patients with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Long-term efficacy of levetiracetam for partial seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Long-term continuation of levetiracetam in patients with refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Levetiracetam as add-on therapy in generalised epilepsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Levetiracetam in autistic children: an open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Mood effects of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Discontinuation of levetiracetam because of behavioral side effects: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016

Efficacy of levetiracetam: a review of three pivotal clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.11.016